Johnson & Johnson will present data from two major studies supporting the performance of its recently FDA-approved Tecnis PureSee IOL at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 10-13 in Washington, DC. Tecnis PureSee IOL is a purely refractive Extended Depth of Focus (EDOF) IOL with improved range of vision compared to a monofocal IOL.¹

“The data presented at ASCRS 2026 confirms that Tecnis PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances,” said Paul Lisenby, Global Head of Research and Development, Vision, Johnson & Johnson. “This evidence underscores our commitment to advancing innovation through rigorous clinical research—extending the range of vision for our patients and reinforcing surgeon confidence.”

Additional presentations will showcase positive results from the broader Tecnis family of IOLs—including evidence of their high tolerance to refractive error and range of vision. New data for Tecnis Odyssey IOL reveals high tolerance in patients with astigmatism, including high spectacle independence, and low rates of severe dysphotopsias. Additionally, new data from the Veritas Vision System showed no measurable endothelial cell count loss.

Notable findings for TECNIS PureSee IOL: 

Results from a US prospective, randomized clinical trial involving over 200 patients across nine sites with Tecnis PureSee IOL show high-quality distance visual acuity, significantly improved intermediate vision vs monofocal control Tecnis 1-pc IOL, with some near vision gained while maintaining contrast sensitivity comparable to an aspheric monofocal IOL and low levels of visual symptoms. Three datasets will be highlighted at the meeting:  

• Quality of Vision Clinical Outcomes for a New Extended Depth of Focus (EDOF) Intraocular Lens (IOL); Donnenfeld, MD– (Abstract)
  • Evaluates the quality of vision of a new purely refractive extended depth of focus IOL in comparison to a standard aspheric monofocal IOL. Data shows Tecnis PureSee IOL provided:
    • Low rates of visual disturbances  
    • Improved intermediate and near vision with higher spectacle independence compared to a monofocal IOL while maintaining contrast sensitivity and comparable distance vision acuity with pupil independent performance 

• Depth of Focus and Visual Performance of a New Purely Refractive Extended Depth of Focus (EDOF) IOL– Daniel Chang DH, MD (Abstract)
  • Evaluates the visual performance and patient reported outcomes of Tecnis PureSee IOL as compared to a standard aspheric monofocal IOL, showing:
    • Strong distance-corrected intermediate vision of 20/28 (mean monocular)
    • Some near vision gained with 1.5 lines of difference over control 
    • A broader range of clear focus, pupil independence performance and overall spectacle independence in most subjects in the Tecnis PureSee IOL group
• Comparison of Tolerance to Refractive Error of a New Purely Refractive Extended Depth of Focus (EDOF) IOL and Standard Monofocal IOL – Thompson, MD (Abstract)
  • Evaluates the clinical tolerance to refractive error of a new purely refractive EDOF IOL as compared to a standard aspheric monofocal IOL, showing:
    • 94% of patients saw distance corrected at 20/25 or better under defocus up to +/- 0.5 diopters indicating good tolerance to refractive error (mean binocular)
    • Additional sub-group analysis showed 97% of EDOF and 94% of control patients were completely or mostly satisfied with their uncorrected overall vision
    • Sub-group analysis also showed 92% of EDOF and 87% of control patients with refractive errors in at least one eye did not need spectacle correction for distance 

To further support the clinical data for Tecnis PureSee IOL, Johnson & Johnson will also share results from a real-world, post-market observation study from over 700 patients across 19 sites in Europe and Asia-Pacific showing excellent clinical outcomes, low bothersome visual symptoms, and high patient satisfaction with limited spectacle use. The lens also demonstrated a high tolerance to post-op refractive errors. Three datasets featured: 

• Real-World Quality of Vision Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Schwam, MD (Abstract)
  • Data reports multicentric real-world quality of vision results of a purely refractive EDOF PCIOL, showing:
    • Mean binocular uncorrected distance vision of 20/19 and best corrected distance vision of 20/18
    • Mean binocular uncorrected intermediate and distance corrected intermediate vision of 20/26
    • Most patients experienced little or no bothersome glare (91%), halos (93%), and (92%) starbursts, respectively
• Real-World Spectacle Independence and Visual Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Shetty, MD (Abstract)  
  • Data reports multicentric real-world spectacle independence and visual outcomes of a purely refractive EDOF PCIOL, showing:  
    • Mean binocular uncorrected distance vision was 20/19 and best corrected distance visionwas 20/18  
    • Spectacle independence was reported in 96% of patients for distance, 95% for intermediate and 61% for near  
    • 93% patient satisfaction across all distances 
• Real-world Performance of New Purely Refractive Extended Depth of Focus (EDOF) IOL in Patients with Residual Post-op Refractive Error – Habeeb, MD (Abstract)  
  • Data evaluates the clinical tolerance to residual refractive errors of a new purely refractive Tecnis EDOF IOL, showing:  
    • Mean binocular uncorrected distance vision was 20/19 in both groups (ametropic and emmetropic) 
    • Most patients reported spectacle independence at distance (91% ametropic and 96% emmetropic)  
    • 95% of ametropic and 92% of emmetropic patients were satisfied with their uncorrected overall vision

Additional Tecnis IOLs will be featured via investigator-initiated studies (IIS):  

• Clinical Outcomes Following Bilateral Implantation of a Next-Generation Intraocular Lens in Patients with Primary Open Angle Glaucoma (POAG); Yuen, MD -  (Abstract)
  • Results in an observational study of visual outcomes following bilateral Tecnis Odyssey IOL implantation in eyes with POAG showed 90% of eyes achieved uncorrected distance vision of 20/25 or better and 87% achieved uncorrected near vision of 20/25 or better
• Tolerance to Simulated Astigmatism and Patient-Reported Outcomes of a Violet Light–Filtering Diffractive Full Visual Range Intraocular Lens - Rocha, MD; Borges, MD (Abstract)  
  • Research showed 90% of patients with up to 1.50 D of with-the-rule astigmatism and up to 1.00 D of against-the-rule achieving distance visual acuity of 20/40 or better
  • 96.6% of patients achieved spectacle independence and low dysphotopsias per the AIOLIS questionnaire

Other IIS Data: 

• Effective Phaco Time and Endothelial Cell Loss Using a Novel Dual Mode Phacoemulsification System - Yuen, MD (Abstract)
  • Interim results show a low mean effective phaco time of 1.67 seconds per phacoemulsification case and no measurable loss in endothelial cells when using the Veritas Vision System
  • There was no change in central corneal thickness compared to baseline at 1 month post-op

Peer-to-Peer Education Events  

To support ophthalmologists in providing the best outcomes for patients and help to elevate their practices, Johnson & Johnson is hosting educational sessions with key opinion leaders throughout the weekend: 

In-booth Virtual Reality Experience: Join J&J in booth #625 for a virtual reality experience to help simulate expected visual outcomes with the Tecnis Odyssey & Tecnis PureSee IOLs. Available during booth hours for a fun, engaging “look into the lens.” 

Veritas Vision System Live Wet Lab Demonstration: Experience advanced infusion technology in booth #625. Sign up for a session here.

• Friday, April 12 – 12:00-5:00pm 

• Saturday, April 12 – 9:00-5:00pm 

• Sunday, April 13 – 9:00-5:00pm  

ASCRS Tap Room Event: Leveraging Premium Tecnis IOL technologies, April 11th 12:00-1:00pm (ASCRS Tap Room, ASCRS Exhibit Hall) 

• Discover the newest IOL in our portfolio and hear practical guidance to help you deliver confident, patient-centered outcomes using the TECNIS platform.